Lysosomal storage diseases are progressive heritable disorders usually caused by deficiencies in lysosomal enzymes. We recently showed that systemic and tissue-directed delivery of recombinant adeno-associated virus (AAV) in neonatal mice with the lysosomal storage disease mucopolysaccharidosis type VII (MPS VII) results in persistent (16 week) beta-glucuronidase (GUSB) expression. The level of expression reduces lysosomal storage in multiple tissues including the central nervous system (CNS). We will now determine if neonatal gene therapy can result in improvements in auditory, visual, cognitive and immune functions. Since these diseases are progressive in nature, it is of interest to determine if in utero gene therapy for LSDs is more efficacious than neonatal therapy. Finally, it has yet to be determined if functional improvements can be achieved in a setting where lysosomal storage is well established, and the clinical defects are present. The goals of this proposal are to determine the consequences of neonatal, in utero and adult AAV-mediated gene transfer in the murine model of MPS VII. We will accomplish these goals with the following specific aims: 1. We will determine the long term clinical effects of systemic and liver-directed AAV-mediated gene transfer in neonatal MPS VII mice. 2. We will determine the effects of direct gene transfer to the brain and eye in young adult MPS VII mice with established disease. 3. We will characterize AAV-mediated in utero gene therapy. A) We will determine the efficacy of in utero gene therapy in the MPS VU mouse. B) We will determine whether in utero gene transfer reduces the immune response to repeated AAV injections in immunocompetent mice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
3R01DK057586-02S1
Application #
6588613
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Mckeon, Catherine T
Project Start
2001-03-01
Project End
2004-11-30
Budget Start
2001-12-02
Budget End
2002-11-30
Support Year
2
Fiscal Year
2002
Total Cost
$55,594
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Hess, David A; Craft, Timothy P; Wirthlin, Louisa et al. (2008) Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells 26:611-20
Meyerrose, Todd E; Roberts, Marie; Ohlemiller, Kevin K et al. (2008) Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 26:1713-22
Zhang, Jessie R; Coleman, Trey; Langmade, S Joshua et al. (2008) Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J Clin Invest 118:2281-90
Sands, Mark S; Haskins, Mark E (2008) CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl 97:22-7
Woloszynek, Josh C; Coleman, Trey; Semenkovich, Clay F et al. (2007) Lysosomal dysfunction results in altered energy balance. J Biol Chem 282:35765-71
Lin, Darshong; Donsante, Anthony; Macauley, Shannon et al. (2007) Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy. Mol Ther 15:44-52
Heldermon, Coy D; Hennig, Anne K; Ohlemiller, Kevin K et al. (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2:e772
Donsante, A; Levy, B; Vogler, C et al. (2007) Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J Inherit Metab Dis 30:227-38
Lin, Darshong; Fantz, Corinne R; Levy, Beth et al. (2005) AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther 12:422-30
Griffey, Megan; Macauley, Shannon L; Ogilvie, Judith M et al. (2005) AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther 12:413-21

Showing the most recent 10 out of 25 publications